Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Integra LifeSciences (Nasdaq: IART) said CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on Integra LifeSciences' investor relations website under Events & Presentations.
Positive
- None.
Negative
- None.
News Market Reaction – IART
In the Jan 6 session, IART gained 4.54%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Conference appearance | Neutral | +0.8% | Management presenting at Citi 2025 Global Healthcare Conference with webcast access. |
| Nov 25 | Policy/reimbursement | Positive | +6.2% | Medicare rules including all Integra skin substitutes with uniform reimbursement rates. |
| Nov 11 | Regulatory clearance | Positive | +1.2% | FDA 510(k) clearance expanding CUSA Clarity use to cardiac surgeries debridement. |
| Oct 30 | Earnings release | Positive | -23.5% | Q3 2025 revenue and EPS growth with updated full-year guidance and relaunch actions. |
| Oct 15 | Earnings call notice | Neutral | -1.2% | Scheduling of Q3 2025 results release and conference call with webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock generally reacted positively to favorable regulatory/policy news and conference updates, but showed a sharp negative move on the Q3 2025 earnings release despite operational growth.
Over the last few months, Integra LifeSciences reported Q3 2025 revenue of $402.1M with 5.6% reported growth and adjusted EPS of $0.54, yet the stock fell 23.46% after that release. Earlier, it received FDA 510(k) clearance for its CUSA Clarity system for cardiac surgeries and benefited from Medicare policy changes that lifted shares 6.17%. Multiple conference-related announcements, including Citi’s 2025 Global Healthcare Conference, saw modest positive or muted reactions. Today’s J.P. Morgan conference appearance fits this pattern of routine investor-relations visibility events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
Integra LifeSciences Holdings Corporation
